CAPN3 mutations in patients with idiopathic eosinophilic myositis
Authors:
- Christophe PécheuxCPChristophe Pécheux
- José L. Pena‐SeguraJPJosé L. Pena‐Segura
- Sandrine Bouillot‐EimerSBSandrine Bouillot‐Eimer
- 10 April 2006
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 59 (6) , 905-911
Abstract
Objective: Eosinophilic myositis (EM) constitutes a rare pathological entity characterized by eosinophilic infiltration of skeletal muscles, usually associated with parasite infections, systemic disorders, or the intake of drugs or L‐tryptophan. The exclusion of such causes defines the spectrum of idiopathic EM. Based on a protein analysis performed in one affected patient, we identified the gene encoding calpain‐3, CAPN3, as a candidate for a subset of idiopathic EM.Methods: We screened CAPN3 for mutations using DHPLC and direct sequencing in six unrelated patients, recruited for EM diagnosed after histological examination of muscle biopsy samples, without any identified causative factor.Results: We identified CAPN3 mutations in the six unrelated patients originally diagnosed with idiopathic EM.Interpretation: Mutations in CAPN3 can cause EM. Thus, a subset of idiopathic EM is genetically determined, with an autosomal recessive mode of inheritance. Patients presented with a triad that appears to be indicative of CAPN3 mutations: (1) EM in the first decade, (2) elevated serum creatine phosphokinase levels (isolated or with little corresponding weakness), and (3) inconstant peripheral hypereosinophilia. However, that EM represents a distinct phenotype associated to CAPN3 mutations or, rather, an early histopathological picture of LGMD2A must be further evaluated. Our findings should be of interest toward further investigating the role of calpain‐3 in skeletal muscle. Furthermore, patients with idiopathic EM should undergo calpain‐3 protein analysis and be considered for subsequent molecular analysis of the CAPN3 gene.Keywords
This publication has 18 references indexed in Scilit:
- Extensive scanning of the calpain-3 gene broadens the spectrum of LGMD2A phenotypesJournal of Medical Genetics, 2005
- LGMD2A: genotype–phenotype correlations based on a large mutational survey on the calpain 3 geneBrain, 2005
- Molecular diagnosis in LGMD2A: Mutation analysis or protein testing?Human Mutation, 2004
- Null mutation of calpain 3 (p94) in mice causes abnormal sarcomere formation in vivo and in vitroHuman Molecular Genetics, 2004
- Fas and Fas-Associated Death Domain Protein Regulate Monocyte Chemoattractant Protein-1 Expression by Human Smooth Muscle Cells Through Caspase- and Calpain-Dependent Release of Interleukin-1αCirculation Research, 2003
- Calpainopathy—A Survey of Mutations and PolymorphismsThe American Journal of Human Genetics, 1999
- Characterization of Monoclonal Antibodies to Calpain 3 and Protein Expression in Muscle from Patients with Limb-Girdle Muscular Dystrophy Type 2AThe American Journal of Pathology, 1998
- Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2ACell, 1995
- Inflammatory response in facioscapulohumeral muscular dystrophy (FSHD): Immunocytochemical and genetic analysesMuscle & Nerve, 1995
- Infantile familial cardiomyopathy due to mitochondrial complex I and IV associated deficiencyNeuromuscular Disorders, 1993